Stocks to Buy: Shares of this ‘super compounder’ can rise another 30%, UBS predicts

According to UBS, Max Healthcare is well-positioned to deliver both capacity expansion and earnings growth. The brokerage said that a CGHS price increase would provide a meaningful tailwind for the company.

Leave a Reply

Your email address will not be published. Required fields are marked *